Search

Displaying results 3551 - 3560 of 4207 in total
  1. Drug

    ARX201

    go.drugbank.com/drugs/DB05082
    Investigational

    human growth hormone that has been modified using Ambrx’s patented ReCODE™ technology to achieve precise spatial positioning of the site of polyethylene glycol (PEG) attachment to human growth hormone, by

  2. Drug

    Ecabet

    go.drugbank.com/drugs/DB05265
    Investigational

    Ecabet represents a new class of molecules that increases the quantity and quality of mucin produced by conjunctival goblet cells and corneal epithelia.

  3. Drug

    Influenza A virus A/Brisbane/10/2010 live (attenuated) antigen

    go.drugbank.com/drugs/DB16517
    Approved

    Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen

  4. Drug

    Influenza A virus A/South Australia/55/2014 live (attenuated) antigen

    go.drugbank.com/drugs/DB16518
    Approved

    Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen

  5. Drug

    Influenza A virus A/Tasmania/503/2020 (H3N2) live (attenuated) antigen

    go.drugbank.com/drugs/DB16718
    Approved

    Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen

  6. Drug

    Influenza A virus A/Victoria/2570/2019 IVR-215 (H1N1) antigen (UV, formaldehyde inactivated)

    go.drugbank.com/drugs/DB16720
    ApprovedWithdrawn

    Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen

  7. Drug

    Influenza A virus A/Victoria/2570/2019 IVR-215 (H1N1) antigen (propiolactone inactivated)

    go.drugbank.com/drugs/DB16722
    ApprovedWithdrawn

    Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen

  8. Drug

    Influenza A virus A/Minnesota/41/2019 (H3N2) recombinant hemagglutinin antigen

    go.drugbank.com/drugs/DB15701
    ApprovedWithdrawn

    Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen

  9. Drug

    Influenza B virus B/Washington/02/2019 recombinant hemagglutinin antigen

    go.drugbank.com/drugs/DB15702
    ApprovedWithdrawn

    Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen

  10. Drug

    Influenza A virus A/Nebraska/14/2019 (H1N1) antigen (MDCK cell derived, propiolactone inactivated)

    go.drugbank.com/drugs/DB15707
    ApprovedWithdrawn

    Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen